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Research indicates that cachexia is common among persons with chronic illnesses and is 
associated with increased morbidity and mortality.  However, there continues to be an absence 
of a uniformed disease specific definition for cachexia in chronic kidney disease (CKD) patient 
populations.   
Objective 
The primary objective was to identify cachexia in patients receiving haemodialysis (HD) using 
Evans et al. generic definition, and then follow up on these patients over 12 months. 
Method 
This was a longitudinal of 106 adult chronic haemodialysis patients attending two hospital HD 
units in the United Kingdom. Multiple measures relevant to cachexia including body mass index 
(BMI), muscle mass (Mid Upper Arm Muscle Circumference; MUAMC), handgrip strength 
(HGS), fatigue (Functional Assessment of Chronic Illness Therapy; FACIT), appetite (Functional 
Assessment of Anorexia/Cachexia Therapy; FAACT) and biomarkers (C-reactive protein (CRP); 
serum albumin;  haemoglobin, and Erythropoietin Resistance Index (ERI)) were recorded.  
Baseline analysis included group differences analysed using independent t-test, dichotomized 
values using the X2 test and prevalence were reported using SPSS 24.  Longitudinal analysis was 
conducted using repeated measures analysis.  
Results 
One hundred and six patients (30 female and 76 male) were recruited with a mean age of 67.6 
years (SD=13.18) and dialysis vintage of 4.92 years (SD=6.12).  At baseline, 17 patients were 
identified as cachectic, having had reported weight loss (e.g. >5% over 6 months) or BMI (<20 
kg/m2) and three or more clinical characteristics of cachexia (7).  Seventy patients were 
available for analysis after 12 months (n=11 cachectic vs. n=59 not cachectic).  FAACT and URR 
statistically distinguished cachectic patients (p=.001).  However, measures of weight, BMI, 
MUAMC, HGS, CRP, ERI and FACIT tended to be worse in cachectic patients.   
Conclusion 
Globally, cachexia is a serious but frequently under-recognised problem. This is the first study 
to apply the defined characteristics of cachexia to a representative sample of patients receiving 
HD. Further larger studies are required to establish a phenotype of cachexia in advanced CKD.  





What is already known about this subject: 
Globally, cachexia is a serious but frequently under-recognised problem. 
It is present in a range of chronic illnesses including cancer, cardiac disease, chronic obstructive 
pulmonary disease, rheumatoid arthritis and chronic kidney disease. 
It is associated with increased morbidity and mortality including, lower quality of life, increased 
depression, higher rates of hospitalization and increased risk of death from cardiovascular 
disease.  However, there is limited evidence about the presence of cachexia in end-stage renal 
disease. 
What this study adds: 
According to a consensus (generic) definition, cachexia is prevalent in patients with renal 
disease receiving haemodialysis. 
What key message do you want to share with readers? 
This is the first study to apply a consensus definition of cachexia to a population of patients 
with renal disease and receiving haemodialysis. 
This study helps to demonstrate the prevalence of cachexia in end-stage renal disease 
including the impact on quality of life. 
In addition, this study helps to demonstrate the challenges of recruiting patients and retaining 
individuals within longitudinal research in this patient group. 
What impact this may have on practice or policy:  
Further research is required to understand if cachexia can be identified as binary 
(present/absent) or still needs to be considered a process of bodily wasting in renal disease. 
Overall, given the impact of cachexia on quality of life of patients with end-stage renal disease 
and the associated high mortality, it is imperative to develop a robust definition to allow for 




Cachexia is present in a range of chronic illnesses including chronic kidney disease (CKD) and is 
associated with increased morbidity and mortality including, lower quality of life, increased 
depression, higher rates of hospitalization and increased risk of death from cardiovascular 
disease (1).  Several operational definitions exist for cachexia regarding it as the most severe 
stage of Protein Energy Wasting (PEW; International Society of Renal Nutrition and 
Metabolism, 2) to a stand-alone disorder (Society of Sarcopenia, Cachexia and Wasting 
Disorders; 3).  PEW and cachexia tend to be used interchangeably in the literature (4) as both 
disorders have overlapping characteristics. However, research had led to the development of 
a clinical phenotype for cancer cachexia and other chronic illnesses (5).  Prevalence of cachexia 
ranges from 5% in rheumatoid arthritis (severe) to 80% in cancer patients (6).  Wasting 
syndromes are common in renal disease and is reported across all CKD stages, although it is 
less common in early CKD (5-9%) compared to advanced CKD stages (20-30% in stage 4-5). The 
highest prevalence of cachexia is in end-stage renal disease (ESRD) and particularly those 
patients on maintenance dialysis (7).  Therefore, the ability to accurately assess and monitor 
cachexia in CKD is an important but potentially underreported aspect of clinical assessment.  
Diagnosing wasting in CKD by estimating measurements of non-oedematous tissue and muscle 
mass is challenging (8). Advanced CKD is associated with multiple symptoms, particularly those 
managed by haemodialysis (HD) (9), experience significant and complex changes to their 
nutritional status and body composition. These alterations to body composition can further 
confound identifying and diagnosing cachexia (10). Cachexia in CKD (e.g. tissue weight loss) is 
often masked (e.g. by oedema/fluctuating hydration status).  These factors alongside the lack 
of a disease specific definition for cachexia in CKD helps to explain why it is less commonly 
recognized in clinical practice (7).   








 Criteria Cut-off point 
Primary 
criteria 
Weight loss or a low BMI Weight loss > 5% over 12 months or a BMI 
<20kg/m2 
AND 




Muscle strength Low handgrip strength (i.e. <27 kg (m)/ <16 kg (f)) 
Fatigue Severe fatigue < 30 
Anorexia Poor appetite < 32 






C-reactive protein (CRP) > 5.0 mg/L 
Anemia Haemoglobin < 120 g/L 
Low serum 
albumin 
Serum albumin < 32 g/L 
 
Evans et al. (3) proposed a generic criteria for diagnosing cachexia in chronic illness with 
appropriate assessment and cut-off points (Table 1) that principally requires evidence of 
unexplained weight loss, low muscle mass and low muscle strength (e.g. by hand grip strength, 
HGS), as well as abnormal biochemistry. Evidence is needed to establish if this definition is 
useful and specific to a HD population, as currently there is no standardized phenotype for the 
identification and assessment of cachexia in ESRD.  Therefore, the aim of this study was to 
identify cachexia in patients with ESRD receiving HD using Evans et al. definition and then 
follow up on these patients for 12 months. 
Methods 
We report a longitudinal study with adult HD patients between September 2017 and April 
2019, who attended two nephrology units within the United Kingdom. Approximately 310 
patients with ESRD receiving HD are cared for between the two nephrology sites.  A prospective 
sample size was calculated. This study sought to and recruited 106 patients which would satisfy 
a 80% confidence level. Patients were eligible for inclusion if they had a confirmed diagnosis of 
ESRD (estimated GFR <15 mL/min/1.73m2) and were receiving HD; were able to read and write 
English and were over 18 years of age (no upper age limit).  Patients were excluded those who 
are Stage 1-4 CKD, Stage 5 CKD who are not receiving haemodialysis, lacking capacity to give 
consent, under the age of 18 or non- english speaking.  
This research collected data (weight, muscle mass, strength, biomarkers, quality of life (KDQoL-
36) via assessments at point of entry into the study and every two months for one year. A single 
research assistant carried out all assessments.  From these data, a diagnosis of cachexia was 
made using the definition proposed by Evans et al. definition (3) for cachexia in chronic illness.   
A minor modification was included and has been validated in the literature (7). This included 
weight loss > 5% over 6 months and > 10% over 12 months allowing for longitudinal assessment 
(beyond 6 months; 3).  
Ethics 
Governance approval for the study was obtained from the host institutions and ethics approval 
from the Office for Research Ethics Committees Northern Ireland prior to the study 
commencing (Research Ethics Committee reference: 16/NI/0233 and United Kingdom Health 
Research Authority).  All patients provided written informed consent and the study was 
conducted in accordance with the principles set out in the declaration of Helsinki. 
Assessments  
At baseline, demographic data and cachectic status (e.g. weight loss / body mass index (BMI) 
and recommended clinical characteristics of cachexia) and other information regarding 
primary renal disease and co-morbidities were recorded. Percentage of weight change of 
patient’s body weight was evaluated at enrollment using medical records. Common 
biochemical parameters including dialysis efficiency (urea reduction ratio (URR)) and estimated 
glomerular filtration rate (eGFR) were also recorded. Baseline and longitudinal assessment 
included twice monthly assessments (+/- one week) of: weight loss of at least 5% > over 6 
months or 10% > over 12 months or less; or a BMI <20 kg/m2. Additional criteria included lean 
tissue depletion (using Mid-Upper Arm Muscle Circumference (MUAMC)), reduced handgrip 
strength, fatigue and abnormal biochemistry; increased inflammatory markers (CRP > 
5.0mg/L), anaemia (haemoglobin < 120 g/L) and low serum albumin (< 32 g/L). Erythropoietin 
resistance index (ERI) was also calculated as a surrogate marker for anemia in this patient 
cohort (weekly erythropoiesis stimulating agent (ESA) dose/ weight (kg) x haemoglobin level 
(g/L). If the patient died at 6 months their data was excluded from longitudinal analysis due to 
missing data. 
Bioelectrical Impedance Analysis (BIA)  
BIA was used to measure phase angle, using a calibrated dual frequency (5 and 50 kHz). 
Bodystat 1500 MDD device (Bodystat, Isle of Man, British Isles). A standard protocol was 
followed with all assessments taken in the post-dialysis period with an aim to control for 
variation in fluid status. Measurements were taken in the supine position, with electrodes 
attached on the hand and foot contra-lateral to the side of the arterio-venous fistula, and at 
constant room temperature. Patients with any implantable electronic devices (such as 
pacemakers) were excluded as per the manufacturer's guidelines.  For those patients that 
could not complete BIA, a BMI was calculated using the clinical formula: weight (kg) divided by 
height2(m). 
Muscle Mass: Mid-Upper Arm Muscle Circumference (MUAMC)  
Mid-arm circumference (MAC) and triceps skinfold (TSF) thickness (TSF in triplicate and the 
average calculated) were measured in the non-fistula arm using a tape measure and 
Harpenden skinfold caliper set, respectively. MUAMC (cm) was calculated using the formula: 
MAMC (cm) = MAC (cm) − 0.314 x TSF (mm) reference.  Suitable cut-point values designated 
5th percentile as a suitable cut-point for low MUAMC and used normal values (i.e., <23.8 cm 
for men and <18.4 cm for women) (11, 12). 
Muscle strength: Handgrip strength (HGS) 
Muscle function includes a range of measures including power, strength, endurance and 
fatigability.  Handgrip strength: Muscle strength was recorded using a standard protocol 
(dominant arm seated position with elbow at 90 degrees allowing three attempts) (13) and 
using a dynamometer (Jamar dynamometer, Patterson, Nottingham, UK).  Specific cut-off 
points were applied based on the European Working Group for Sarcopenia in Older People 
(EWGSOP) for muscle strength (<27 kg for males and <16 kg for females) (14).   
Fatigue: FACIT 
Fatigue was recorded using Functional Assessment of Chronic Illness Therapy (FACIT v4, 15).  
Brown and colleagues (16) reported strong correlations between ‘chair-rise’ time test and 
FACIT suggesting it is a reliable measure of physical function.  Lower scores of the FACIT 
subscale for fatigue refers to increased fatigue. The optimal cut-off value for FACIT is <30 (17). 
Anorexia: FAACT 
Appetite was recorded using the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) 
(18).  Lower FAACT subscale for anorexia reflects poor appetite.  The optimal cut-off value for 
FAACT is <32 (19).    
Analysis  
Statistical analysis was performed using SPSS Version 24 (20).  Baseline analysis included 
descriptive results at each time point which are presented as mean + standard deviation.  Sex 
specific cut-points were applied to relevant data (HGS, MUAMC).  Baseline analysis included 
group differences analysed using independent t-test.  Dichotomized values were compared 
using the X2 test.  Longitudinal analysis was conducted using repeated measures analysis. 




One hundred and six patients (30 female and 76 male) were recruited, and at baseline, 17 
patients were identified as having cachexia: 13 patients had >5% of weight loss and four had a 
recorded BMI <20kg/m2.  All 17 patients had three or more clinical characteristics of cachexia 
(3).  Eighty-nine patients were identified as not cachectic.   
Table 2. Baseline characteristics  
 All n=106 Cachectic n=17 Not cachectic n=89 Sig. 
Sex, Female (%) 30 (28) 7 (41) 23 (25.8) n.s. 
Age, yrs (sd) 67.62 +/-13.18 66.71 +/-11.44 67.80 +/-13.54 n.s. 
% >65 years  63% 64% 59% - 
Years on dialysis M (sd)  4.92 +/- 6.12 2.78 +/-3.04 5.34 +/-6.49 n.s. 
Catheter access  
(vs. central line) 
84.9% 76.5% 86.5% n.s. 
CCI, score  6.10 +/- 2.30  6.65 +/-1.73 6.00 +/-2.39 n.s. 
Diabetes, % 52% 24% 56% - 
Cancer, % 25% 18% 26% - 
BMI kg/m2 * 28.0 (23.0-31.3) 23.0 (20.0-29.5) 28.0 (24.0-32.0) n.s. 
Weight kg/m2 * 81.3 (65.2-91.2) 62.2 (55.1-84.7) 82.6 (67.4-93.0) n.s. 
URR * .73 (69-.77) .75 (.72-.81) .73 (.68-.77) <.001 
eGFR * 8.2 (6.5-6.9) 6.8 (5.5-6.8) 8.6 (6.9-10.7) n.s. 
Phase Anglea* 5.1 (4.3-5.7) 5.5 (4.8-5.8) 4.9 (4.15-5.7) n.s. 
















CRP mg/L * 10.6 (3.0-19.6) 17.0 (6.8-31.8) 8.0 (3.0-17.8) n.s. 
Serum albumin g/L * 37.5 (34.0-40.0) 37.0 (34.0-39.5) 38.0 (34.5-40.0) n.s. 
Haemoglobin g/L * 113.0 (104.0-119.0) 113.0 (104.5-124.0) 113.5 (103.5-119.0) n.s. 
ERI * 37.9 (16.3-82.5) 43.3 (31.8-92.4) 31.6 (15.1-82.7) n.s. 
FAACT (ACS) 37.24 +/-7.39 30.53 +/-10.48 38.52 +/-5.90 .001 
FACIT  32.53 +/-12.27 27.00 +/-12.21 33.58 +/-12.07 n.s. 
KDQOL-36 
Symptoms/problems list 
78.71 +/-15.24 68.01 +/-17.34 80.76 +/-14.00 
n.s. 
KDQOL-36  
Effect of kidney disease 
78.36 +/-20.44 67.47 +/-26.17 80.44 +/-18.62 
n.s. 
KDQOL-36  
Burden of kidney 
disease 





KDQOL-36 PCS SF-12 37.92 +/-10.37 33.29 (11.04 38.80 +/-49.25 n.s. 
KDQOL-36 MCS SF-12 48.25 +/-11.91 43.01 (13.96 49.25 +/-11.29 n.s. 
N=number; M=Mean (SD=standard deviation); *=median (IQR=Interquartile range); a Reported by n=87; 
BMI=Body Mass Index; URR=dialysis UREA clearance; eGFR=estimated glomerular filtration rate; MUAMC=Mid 
upper arm muscle circumference; HGS= handgrip strength; CRP=C-reactive protein; ERI= erythropoietin 
resistance index; FAACT= Functional Assessment of Anorexia Cancer Therapy; FACIT= Functional Assessment 
of Chronic Illness Therapy; KDQoL-36=Kidney Disease Quality of Life; PCS SF-12= Physical component score 
short form 12; MCS SF-12= Mental Component Score short form 12; CCI=Charlson Comorbidity Index; m/f; 
male/female; Yrs=years. 
 
Table 2 provides mean (M) baseline scores of all, cachectic and not cachectic patients.  
Bonferroni correction was applied. Cachexia prevalence in this patient sample was 16% (n=17).  
Independent t-test demonstrated that only URR (p<.001) and FAACT (p=.001) were significantly 
different at baseline between those with cachexia and those without.  URR was higher in 
patients with cachexia than those without cachexia (M=1.2, SD=1.95 vs. M=.71, SD=.10).  
Appetite was poorer in patients with cachexia than those without cachexia (M=30.53, 
SD=10.48 vs. M-38.52, SD=5.90). 
Longitudinal results 
Table 3. Attrition information for all patients (and those identified as cachectic at baseline) 
after 12 months 
 Total Died Tx 
Lost to 
follow up 

















































N=number; Tx=transplant; WD=withdrawn; HPD=Home peritoneal dialysis 
 
The majority of patients (n=70) were included at the final assessment point (time 6; Table 3).   
Thirty patients identified at baseline as not cachectic were not followed up (8 died, 14 
transplanted, 5 withdrew and 3 started home peritoneal dialysis). Six patients identified at 
baseline as cachectic were not followed up (5 died, 1 lost to follow up). Longitudinal follow up 
included 11 patients identified as cachectic at baseline and 59 patients identified as not having 
cachexia (Appendix 2).   
 
Figure 1. Mean change scores of clinical characteristics of cachexia between baseline and 





Figure 1 shows significant changes in HGS, FACIT and FAACT after 12 months for the 70 patients 
who remained in the study. After normality checks a repeated measures analysis was 
conducted using Greenhouse-Geisser correction for cachectic and not cachectic groups. 
Cachectic group: showed a significant main effect of time on HGS (p<.001), FACIT (p<.001), and 
FAACT (p<.001).  Post hoc tests with Bonferroni correction revealed significant decreases for 
FACIT (baseline vs. time 6, p<.01) and FAACT (baseline vs. time 6, p=.01). A significant decrease 
in HGS was reported (baseline vs. time 6, p<.01).  Non-cachectic group: showed significant 
effect of time on HGS (p<.001), FACIT (p<.001) and FAACT (p<.001).   FACIT and FAACT declined 
significantly between baseline and time 6 (p=.02, p=.01 respectively).  HGS also significantly 



















*  *  *  
*indicates a statistically significance difference, C=cachectic; NC= not cachectic; BMI=Body Mass Index; MUAMC= Mid upper arm muscle circumference; HGS= handgrip 
strength; CRP=C reactive protein; Alb= serum albumin; Hb= Haemoglobin; FACIT= Functional Assessment of Chronic Illness Therapy; FAACT= Functional Assessment of Anorexia 
Cancer Therapy 
  
This study assessed whether the criteria for cachexia, proposed by Evans et al. (3), could be 
applied to a representative sample of HD patients at baseline with subsequent follow up every 
2 months to a final time point at 12 months. The study evaluated whether cachexia 
characteristics were present at baseline and to what extent these measurements of cachexia 
changed over time. The results suggest that cachexia is common in ESRD patients treated with 
HD, as 16% of the sample were classified as cachectic at baseline.  Reduced appetite and low 
handgrip strength helped to distinguish between cachectic and non-cachectic patients 
whereas low muscle mass, fatigue and biomarkers were not. However, despite a lack of 
significant differences, overall measures of weight, BMI, MUAMC, HGS, CRP, ERI, FAACT and 
FACIT were worse in those identified as cachectic at baseline.  Although anaemia and increased 
inflammatory markers were common in both groups.  Conversely, neither the cachectic or non-
cachectic groups had significant hypoalbuminaemia.  Surprisingly, dialysis adequacy was 
significantly better in the cachectic group however measurements of URR can vary 




In absence of recorded weight loss, a BMI of less than 20 kg/m2 can be used as the primary 
criterion for cachexia (3). It has been useful in this patient cohort at identifying patients with 
‘kidney cachexia’.  However, BMI requires further investigation.  Over 60% of this patient 
sample were either overweight or obese which is consistent with other renal studies (22). This 
may be associated with the higher prevalence of diabetes-related in ESRD (Table 2). In addition, 
it has been suggested that BMI cut-offs may misrepresent the degree of adverse outcomes in 
older populations (23, 24) and caution should be used when interpreting.   
MUAMC provides a measure of muscle mass.  After Bonferroni correction, no significant 
differences between patient groups at baseline were reported. However, clinical cut-offs for 
low muscle mass were reached indicating muscle catabolism in common in this cohort.  
Longitudinal assessment highlighted a declining trajectory however this was not statistically 
significant between baseline and follow up. There is a clear need to routinely monitor muscle 
mass in CKD, however gold standard assessment measures although more accurate (e.g. DEXA; 
8) are difficult to incorporate into routine clinical practice in HD patients. Ventor impedance 
analysis was not possible due to the small sample size and respective missing data however 
this technique is useful in CKD patient populations to assess muscle mass independently of the 
hydration status (25). 
Mean scores of muscle strength, measured by HGS were very low in all groups and met clinical 
cut offs at baseline for cachectic males but not female patients. This may be explained by the 
small number of females recruited. Longitudinal analysis demonstrated further statistically 
significant decline in HGS in both groups. According to the EWGSOP recommended criteria, 
this cohort exhibited clinically low levels of grip strength, an important indicator of sarcopenia 
and frailty (14; <27kg for males; <16kg for females) highlighting potential overlap with other 
disorders (26).  It is also argued that CKD accelerates the aging process which helps to explain 
why the frailty phenotype is commonly reported in CKD patient populations (27).  Such clinical 
overlap with cachexia requires further investigation in CKD.   
CRP is the most widely agreed biomarker of metabolic abnormality in cancer cachexia (28).  
Results from the current study also indicate that patients with ESRD receiving HD also have 
raised CRP levels at multiple time points consistent with chronic inflammation.  Evidence 
suggests that inflammation in patients with advanced CKD is multifactorial and not uncommon 
(29).  Therefore, the cut off value for CRP levels in an ESRD population needs to be revised to 
a higher level than 5mg/L.   
Levels of serum albumin were not useful in identifying patients with weight loss or cachexia. 
While albumin concentration is widely used to measure nutritional status this is confounded in 
patients receiving HD.  It is recommended that no single marker should be used to assess 
nutritional status in renal disease (30). This is because serum albumin is influenced by a range 
of factors such as fluid balance status, proteinuria and acute inflammation (31).  Lower serum 
albumin levels are also associated with persistent systemic inflammation (32) and may fall 
further as chronic disease progresses (33).  Surprisingly at baseline, albumin was found to be 
higher in the cachectic group and this trend was observed at the end of the study. Fujiwara 
and colleagues (34) demonstrated that serum albumin can show substantial intra-day 
variation, which may help to explain the current results.  Longitudinal monitoring should be 
combined with time of recording as well as comparative assessment.   
Similar to serum albumin, haemoglobin did not differ statistically between groups. Clinical 
practice guidelines suggest that haemoglobin levels in HD patients should be maintained within 
an optimal range of 100-120g/L with the use of ESAs and intravenous iron.  It is therefore not 
surprising the mean haemoglobin levels of HD patients in this study were below the 
haemoglobin concentration of 120g/L proposed as a marker for cachexia (3, 35).  Compared to 
the trajectory of ERI, a surrogate marker for anemia maintenance, haemoglobin was less useful 
as a cachexia marker in ESRD (36).  As CKD progresses, haemoglobin levels tend to fall 
necessitating the use of ESAs to increase haemoglobin and reduce the clinical impact of more 
severe anaemia.  Scores of ERI were higher in cachectic patients suggesting such patients 
require increased dosages of ESAs to remain within the optimal range of 100-120g/L.  
Patients categorised as cachectic at baseline also reported significantly poorer appetite. 
Longitudinal analysis also demonstrated appetite significantly decreased for both groups by 
the end of the study.  Prevalence of poor appetite or anorexia is reportedly to range between 
25% to 61% in ESRD (37) and is associated with increased likelihood of hospitalisation reduced 
quality of life and higher mortality (38).   However, to date, little is known about the direct or 
indirect impact of anorexia/poor appetite and its relationship with cachexia in ESRD.  
Prescribed drugs and supplements also interfere with appetite and should be carefully 
considered when using appetite as a useful predictor of cachexia. Despite this, the FAACT 
assessments is regarded as a valid tool in HD patients to discriminate anorexia (39). 
Participants in the cachectic group also had greater fatigue at baseline, but this was not 
significantly different at baseline. This is not surprising as fatigue is one of the most frequent 
reported symptoms and affects 60-97% of ESRD patients (40).  In addition, fatigue increased 
for both groups by the end of the study.  When comparing mean scores for fatigue in cancer 
patients with cachexia, using the same validated tool as used within this study (FACIT; 15) it is 
noteworthy that ESRD patients at risk of cachexia demonstrated fatigue similar to or greater 
than cachectic cancer patients. This helps to contextualise the impact of fatigue on ESRD 
populations and how this may be severely exacerbated in cachectic ESRD patients (41), an 
aspect not explored extensively in ESRD. 
Limitations 
The degree of attrition experienced over time in this study is similar to other renal studies (42) 
and helps to demonstrate the challenges of recruiting patients and retaining individuals within 
longitudinal research in this patient group.  Of note patients did not differ statistically on age 
or comorbidity levels however this should be considered as confounding the results.   It is 
important to highlight that 52 patients were excluded at the recruitment stage for being “very 
unwell” (deemed medically unfit to participate by clinical staff; see Appendix 1).  Five patients 
were also withdrawn during the course of the study (Table 3) which may also cause bias.  In 
addition, only one measure of Evans et al. definition (3) statistically distinguished cachectic and 
non-cachectic patients; a subjective assessment of appetite.  Future studies should consider 
objective assessment of nutritional intake. This study also had a relatively small sample size, 
with resultant limitations in interpreting the data.  Survival analysis was not reported however 
29% of cachectic patients died during the study compared to 9% of non-cachectic patients. 
There is a need to examine mortality and associated comorbidities in larger prospective 
medical data taking account of cachexia.  Overall the current study has strengths which include 
the recruitment and retention of 66% of the cohort which helps to increase the generalizability 
of the study. 
Conclusion 
Globally, cachexia is a serious but frequently under-recognised problem. This is the first study 
to apply the known characteristics of cachexia to a representative sample of patients receiving 
HD. Overall significant differences were limited however measures of muscle strength and 
reduced appetite are crucial in distinguishing between cachectic and not cachectic patients. 
Additionally, measures of weight, muscle mass, BMI, CRP, ERI and fatigue were worse in those 
identified as cachectic at baseline.  However, it is important to note this was a pilot study and 
future studies should aim to increase the sample to reach the sample size to give greater 
reliability and95% CI address aforementioned study biases.  Further research is required to 
demonstrate if Evans et al. definition (3) identifies cachexia as binary (present/absent), moving 
away from a process (1).  Given the impact of cachexia on quality of life of patients with ESRD 
and the associated high mortality, it is imperative to develop a robust definition to allow for 
future feasibility testing of interventions for cachexia currently absence from renal guidelines. 
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